Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
70 hedge funds and large institutions have $251M invested in Progenics Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 20 closing their positions.
5% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 22
3% less capital invested
Capital invested by funds: $258M → $251M (-$6.61M)
16% less funds holding
Funds holding: 83 → 70 (-13)
64% less call options, than puts
Call options by funds: $484K | Put options by funds: $1.33M
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$2.75M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.29M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$545K |
| 4 |
JG
Jefferies Group
New York
|
+$532K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$506K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.4M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$3.17M |
| 3 |
Morgan Stanley
New York
|
-$1.82M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$1.7M |
| 5 |
Renaissance Technologies
New York
|
-$1.41M |
PGNX Hedge Fund Activity: Q4 2013 in Review
70 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2013, worth a combined $251M — down 2.6% from $258M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PGNX and 7 opened new positions — a net loss of 13 holders — while 22 trimmed existing stakes and 23 added.
The largest buyer was Phocas Financial Corp, opening a new position worth an estimated $2.75M. The largest seller was Fidelity Investments, cutting an estimated $11.4M.
- 70 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2013, down from 83 in Q3 2013.
- Funds reported $251M of Progenics Pharmaceuticals Inc stock for Q4 2013, down 2.6% quarter-over-quarter.
- 7 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2013 and 20 closed out, a net change of -13 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2013 was Phocas Financial Corp, an estimated $2.75M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2013 was Fidelity Investments, an estimated $11.4M sold.
Based on aggregated 13F filings for Q4 2013.